阅读说明：本技术 一种用于预防和治疗炎症性肠病的绿色健康药物 (Green and healthy medicine for preventing and treating inflammatory bowel diseases ) 是由 彭佼 肖海涛 郑婷婷 黄永灿 李�杰 梁悦 王立军 陈芸 于 2021-03-08 设计创作，主要内容包括：本发明属于药品技术领域,具体涉及一种用于预防和治疗炎症性肠病的绿色健康药物,其特征在于：该用于预防和治疗炎症性肠病的绿色健康药物的主成份为板蓝根颗粒,板蓝根颗粒由板蓝根或板蓝根和大青叶组成,可来源于已上市的OTC药物板蓝根颗粒及复方板蓝根颗粒。本申请可以达到和临床一线药物SASP相当的治疗效果,相比现有药物具有疗效好、费用低、安全性高、绿色健康的优点。(The invention belongs to the technical field of medicines, and particularly relates to a green and healthy medicine for preventing and treating inflammatory bowel diseases, which is characterized in that: the main component of the green and healthy medicine for preventing and treating the inflammatory bowel disease is the isatis root granules, the isatis root granules consist of isatis root or isatis root and dyers woad leaf, and can be sourced from OTC medicine isatis root granules and compound isatis root granules on the market. The application can achieve the treatment effect equivalent to that of a first-line clinical medicine SASP, and has the advantages of good curative effect, low cost, high safety, greenness and health compared with the existing medicine.)

1. A green and healthy medicament for preventing and treating inflammatory bowel disease, characterized by: the green health medicine for preventing and treating inflammatory bowel diseases comprises isatis root granules as a main component.

2. The green health drug for the prevention and treatment of inflammatory bowel disease according to claim 1, characterized in that: the radix Isatidis granule comprises indioside, isatin, indigo, indirubin, tryptanthrin, adenosine, cytidine, uridine and guanosine.

3. The green health drug for the prevention and treatment of inflammatory bowel disease according to claim 1, characterized in that: the radix Isatidis granule comprises radix Isatidis or radix Isatidis and folium Isatidis.

4. The green health drug for the prevention and treatment of inflammatory bowel disease according to claim 3, characterized in that: the radix Isatidis is prepared from dried rhizome and root of herba Kalimeridis of Acanthaceae; folium Isatidis is prepared from leaf of Isatis indigotica of Brassicaceae.

5. The green health drug for the prevention and treatment of inflammatory bowel disease according to claim 1, characterized in that: the radix isatidis particle is sourced from OTC medicines and/or compound radix isatidis particles on the market.

6. The green health drug for the prevention and treatment of inflammatory bowel disease according to claim 1, characterized in that: the radix Isatidis granule comprises alkaloid compounds, flavonoid compounds, organic acid compounds, glycosides, sterols, pentacyclic triterpene compounds, anthraquinone compounds, amino acid compounds, and saccharide compounds.

7. The green health drug for the prevention and treatment of inflammatory bowel disease according to claim 6, characterized in that:

the alkaloid compounds comprise one or more of indioside, isatin, indigo, indirubin and tryptanthrin;

the amino acid compound comprises one or more of glycine, alanine, serine, proline, valine, threonine, cysteine, isoleucine, leucine, aspartic acid, tyrosine, tryptophan, cystine, glutamic acid, methionine, phenylalanine, arginine, lysine and histidine;

the glycoside component comprises one or more of sinigrin, glucose brassin, new glucose brassin and 1-sulfo-3-indolylmethyl glucosinolate;

the organic acid compound comprises one or more of palmitic acid, benzoic acid, salicylic acid, 2-aminobenzoic acid and syringic acid;

the pentacyclic triterpenoid comprises one or more of lupeol, lupeol and betulin;

the anthraquinone compounds comprise chrysophanol;

the saccharide compound comprises one or more of sucrose and polysaccharide.

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to a green and healthy medicine for preventing and treating inflammatory bowel diseases.

Background

Inflammatory Bowel Disease (IBD), including Ulcerative Colitis (UC) and Crohn's Disease (CD), is one of the most common chronic digestive diseases in the clinic. According to statistics, inflammatory bowel diseases are frequently found in western countries, but with the changes of social environment exposure, life style and drinking structure, the number of patients suffering from inflammatory bowel diseases in China is on a remarkable increasing trend, and the inflammatory bowel diseases become one of the most main diseases of the digestive system in China. The inflammatory bowel disease is clinically mainly manifested by symptoms of abdominal pain, diarrhea, mucus, bloody stool and the like, is prolonged, is easy to attack repeatedly, can generate serious complications to induce colon cancer, and is listed as one of modern refractory diseases by WHO. The patients are young and strong mostly, and tend to be younger, which seriously affects social productivity and personal life quality and even endangers life. Since the specific etiology of IBD is not clear, conventional drug therapy is difficult to achieve the purpose of radical treatment, and side effects are likely to occur. Therefore, finding effective and safe treatment strategies is a hotspot and difficulty in current IBD control.

At present, clinically, the drugs mainly rely on aminosalicylates, steroids, azathioprines, biological agents and the like to induce remission and prevent relapse, the long-term curative effect is not ideal, the side effect is large, and safe, effective and cheap drugs are urgently needed in clinic. Because the new drug research and development period is long, the investment is large, and the success rate is low; huge expenses are invested in the development of new anti-IBD drugs worldwide every year, but no new drug breakthrough with good clinical effect exists. The traditional Chinese medicine has the advantages of multiple components, multiple targets, small side effect, high safety and low price, and has unique advantages in preventing and treating complex diseases such as IBD (infectious bronchitis); especially, the safety and effectiveness of the Chinese patent medicine which is handed over to the modern ancient classic famous prescription and the Chinese pharmacopoeia have been tested by long-term clinical practice. Therefore, the effective medicine for treating IBD is discovered from the ancient classical famous prescription on the market and the Chinese patent medicines collected and carried in the Chinese pharmacopoeia, which can save the time and the cost of developing new medicines, reduce the risk of developing new medicines and has high success rate and popularization value.

Disclosure of Invention

In view of the above, the present invention provides a green health medicine for preventing and treating inflammatory bowel disease, so as to solve the technical problems in the prior art.

The solution adopted by the invention to solve the technical problem is as follows:

a green and healthy medicament for preventing and treating inflammatory bowel disease, characterized by: the green health medicine for preventing and treating inflammatory bowel diseases comprises isatis root granules as a main component.

Preferably, the isatis root granules contain indioside, isatin, indigo, indirubin, tryptanthrin, adenosine, cytidine, uridine and guanosine.

Preferably, the radix isatidis granules consist of radix isatidis or radix isatidis and folium isatidis.

Preferably, radix Isatidis is prepared from dried rhizome and root of herba Kalimeridis of Acanthaceae; folium Isatidis is prepared from leaf of Isatis indigotica of Brassicaceae.

Preferably, the radix isatidis particle is sourced from OTC medicines which are already on the market and/or compound radix isatidis particles.

Preferably, the radix Isatidis granule comprises alkaloid compounds, flavonoid compounds, organic acid compounds, glycosides, sterols, pentacyclic triterpene compounds, anthraquinone compounds, amino acid compounds, and saccharide compounds.

Preferably, the alkaloid compound comprises one or more of indioside, isatin, indigo, indirubin and tryptanthrin; the amino acid compound comprises one or more of glycine, alanine, serine, proline, valine, threonine, cysteine, isoleucine, leucine, aspartic acid, tyrosine, tryptophan, cystine, glutamic acid, methionine, phenylalanine, arginine, lysine and histidine; the glycosides component comprises one or more of sinigrin, glucose brassin, new glucose brassin, and 1-thio-3-indolylmethyl glucosinolate; the organic acid compound comprises one or more of palmitic acid, benzoic acid, salicylic acid, 2-aminobenzoic acid and syringic acid; the pentacyclic triterpenoid comprises one or more of lupeol, and betulin; anthraquinone compounds include chrysophanol; the saccharide compound comprises one or more of sucrose and polysaccharide.

The beneficial technical effects are as follows:

the green and healthy medicine for preventing and treating inflammatory bowel diseases, disclosed by the application, adopts natural isatis roots as a main component, can achieve a treatment effect equivalent to that of a clinical first-line medicine SASP through a living mouse model comparison test, and has the technical effects of good curative effect, low cost, safety, no toxicity, green, health and the like compared with the prior art.

The technical solutions and technical effects of the present application will be described in detail below with reference to the drawings and the detailed description of the present application.

Drawings

FIG. 1: replication of chronic inflammatory bowel disease models and dosing regimens of isatis root granules;

FIG. 2: a model disease activity index comparison map;

FIG. 3: a comparison graph of the length of the model colon;

FIG. 4: comparing the pathological changes of the intestinal organs;

FIG. 5: FIG. 4 is a graph comparing quantification scores;

FIG. 6: a comparative plot of TNF-alpha mRNA gene levels;

FIG. 7: a map of IL-1. beta. mRNA gene levels;

FIG. 8: a map of IL-6mRNA gene levels;

FIG. 9: a graph comparing TNF-alpha protein levels;

FIG. 10: a comparison of IL-1 β protein levels;

FIG. 11: a comparison of IL-6 protein levels;

BLG-isatis root-treated group, SASP-sulfasalazine-treated group, CON-blank control group (no DSS chemical agent causing inflammatory bowel disease), DSS model group- (DSS chemical agent causing inflammatory bowel disease model group).

Detailed Description

Referring to FIG. 1, a three-cycle, cyclically replicating mouse model of chronic inflammatory bowel disease was performed using 1.8% dextran sulfate sodium salt (DSS MW: 36000-50000) with intervention at the start of the experiment by administering Isatis root granules (BLG group, sugar-free, 2g/kg, oral) and sulfasalazine (SASP group, 200mg/kg, oral), respectively. By using a classical chronic inflammatory bowel disease model as an experimental model of the green health drug for treating inflammatory bowel disease in the present application, a model mouse was freely drunk, the water contained 1.8% DSS in concentration for 5 days, then distilled water was drunk for 7 days, then 1.8% DSS was drunk for 5 days, then distilled water was drunk for 7 days, and then distilled water was drunk for 7 days until day 36, and a model mouse of inflammatory bowel disease was built. And then, performing index evaluation, comparison and drawing on experimental results of the BLG group, the SASP group, the DSS model group and the blank control group. Various index comparison graphs of fig. 2-11 were obtained.

The results of the experiment, please refer to fig. 2-11:

figure 2 effect of isatis root granules on disease activity index of chronic inflammatory bowel disease mice: radix Isatidis granule (BLG, sugar-free type, 2g/kg, oral) and sulfasalazine (SASP, 200mg/kg, oral) can reduce disease activity index of chronic inflammatory bowel disease mice; the two effects are equivalent.

Figure 3 effect of isatis root granules on colon length in chronic inflammatory bowel disease mice: the radix Isatidis granule (BLG) and sulfasalazine (SASP) can inhibit colon length shortening of mice with chronic inflammatory bowel disease, and have equivalent effect.

In FIG. 4, it can be seen from the photographs of the lesion group (DSS model group) that the intestinal structure of the mice is disordered, a large amount of inflammatory cells are infiltrated, the intestinal edema is caused, and the length of the colon is shortened. The intestinal structures of mice in the SASP group and the BLG group are recovered to different degrees, so that the pathological score of the colon of the mice with chronic inflammatory bowel disease can be reduced, and the effects of the intestinal structures of the mice are equivalent.

Fig. 5 is a quantitative score of pathological changes in intestinal organs, from which a conclusion consistent with fig. 4 can be drawn.

FIG. 6, FIG. 7 and FIG. 8 are graphs comparing the expression of mRNA gene levels of inflammatory factors TNF-. alpha.IL-1. beta. and IL-6 in group 4, respectively. The radix Isatidis granule group (BLG) can reduce the mRNA expression of inflammatory factors TNF-alpha, IL-1 beta and IL-6 in colon tissue of mice with chronic inflammatory bowel disease, and has the same effect as SASP group.

FIGS. 9, 10 and 11 are graphs comparing the protein level expression of the inflammatory factors TNF-. alpha.IL-1. beta. and IL-6 in 4 model groups, respectively. As can be seen from FIG. 9, the Isatis root granule group (BLG) reduced the expression of protein levels of the inflammatory factors TNF-. alpha., IL-1. beta., and IL-6 in colon tissue of mice with chronic inflammatory bowel disease, with an effect comparable to that of the SASP group.

The experimental results show that the green and healthy medicine for preventing and treating inflammatory bowel diseases disclosed by the application can achieve the treatment effect equivalent to that of a first-line clinical medicine SASP, and has the technical effects of good curative effect, low cost, safety, no toxicity, green and health and the like compared with the existing medicines.

While the invention has been described in detail and with reference to the drawings and specific embodiments thereof, it should be understood that the specific embodiments disclosed in the specification are merely exemplary embodiments of the invention, and that other embodiments may be developed by those skilled in the art; any simple modifications and equivalents without departing from the innovative concept of the present invention are intended to be included within the scope of the present patent.